Skip to main content
What types of page to search?

Alternatively use our A-Z index.

Publications

What type of publication do you want to show?

2024

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.

Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., . . . Owen, A. (2024). Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.. Microbiology spectrum, 12(8), e0391623. doi:10.1128/spectrum.03916-23

DOI
10.1128/spectrum.03916-23
Journal article

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.

DOI
10.1101/2024.03.03.583160
Preprint

2023

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.

DOI
10.1101/2022.01.23.477397
Preprint

2022

Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.

DOI
10.1101/2022.03.03.482788
Preprint

2021